Gilead Sciences (GILD) : Odey Holdings Ag reduced its stake in Gilead Sciences by 35.37% during the Q4 period. The investment management company now holds a total of 3,445 shares of Gilead Sciences which is valued at $310,980 after selling 1,885 shares in Gilead Sciences according to the most recent disclosure to the SEC.Gilead Sciences makes up approximately 2.65% of Odey Holdings Ag’s portfolio.
Other Hedge Funds, Including , Menora Mivtachim Holdings Ltd. boosted its stake in GILD during the Q4 period, The investment management firm added 750 additional shares and now holds a total of 502,260 shares of Gilead Sciences which is valued at $45.3 Million. Gilead Sciences makes up approx 3.03% of Menora Mivtachim Holdings Ltd.’s portfolio. Laurion Capital Management Lp added GILD to its portfolio by purchasing 72,200 company shares during the Fourth Quarter which is valued at $6.5 Million. Gilead Sciences makes up approx 0.46% of Laurion Capital Management Lp’s portfolio.Meiji Yasuda Asset Management Co Ltd. boosted its stake in GILD during the Q4 period, The investment management firm added 1,802 additional shares and now holds a total of 45,155 shares of Gilead Sciences which is valued at $4.1 Million. Gilead Sciences makes up approx 0.93% of Meiji Yasuda Asset Management Co Ltd.’s portfolio.Thornburg Investment Management Inc reduced its stake in GILD by selling 345 shares or 0.07% during the fourth quarter. The Hedge Fund company now holds 483,049 shares of GILD which is valued at $43.6 Million. Gilead Sciences makes up approx 0.28% of Thornburg Investment Management Inc’s portfolio.United Asset Strategies boosted its stake in GILD during the Q4 period, The investment management firm added 2,030 additional shares and now holds a total of 58,962 shares of Gilead Sciences which is valued at $5.3 Million. Gilead Sciences makes up approx 2.25% of United Asset Strategies’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .
Gilead Sciences opened for trading at $94.35 and hit $95 on the upside on Monday, eventually ending the session at $94.24, with a gain of 0.13% or 0.12 points. The heightened volatility saw the trading volume jump to 88,04,802 shares. Company has a market cap of $128,812 M.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.